

26 March 2018

NSX Announcement

SPONSORED RESEARCH AGREEMENT WITH COLUMBIA UNIVERSITY

Beroni Group Limited (“Beroni” or the “Company”) is pleased to announce that it has entered into an agreement with the Columbia University, New York (“Columbia University”), to provide US\$1 million funding to a 12-month research program in the field of ArboViroPlex rRT-PCR Test, a multiplex assay that can simultaneously test for Zika virus, all dengue virus serotypes, Chikungunya virus and West Nile virus (“Research”), under the direction of Professor Walter Ian Lipkin. Columbia University will furnish the Company with a final report of the Research within ninety (90) days following the end of the research period (“Final Research Report”).

The funding support is payable within 10 days of signing this agreement. In return for the research funding support, Columbia University grants the Company an exclusive option (“Option”) to:

- Obtain an exclusive, compensation bearing license in the territory of China to the background patents and inventions in the field of ArboViroPlex rRT-PCR Test, a multiplex assay that can simultaneously test for Zika virus, all dengue virus serotypes, Chikungunya virus and West Nile virus; and
- A non-exclusive, compensation bearing license in the territory of China to the information and materials developed in the course of Research (as each term is hereinafter defined) in the field of ArboViroPlex rRT-PCR Test.

The term of the Option will commence on the Effective Date and will expire ninety (90) days after the date of Company’s receipt of the Final Research Report (“Option Period”). The Option Period may be extended by written agreement of Columbia University and the Company. If the Company elects to exercise the Option, Columbia University and the Company will promptly commence negotiation of a License Agreement in good faith.

Subject to IP registration and maintenance, the Company and Columbia University will execute the License Agreement no later than three (3) months after the date of the exercise of the Option (“Negotiation Period”). Columbia University will not offer, sell, transfer, assign or enter into any license or grant any rights to the background patents and invention in field of ArboViroPlex rRT-PCR Test or negotiate the same with any commercial third party during the Option Period and Negotiation Period.

Beroni Chairman, Mr Jacky Zhang said: *“The funding arrangement signifies the first investment by Beroni in advanced biomedical research program lead by world renowned institution. Through information sharing and staff training during the Research, and the subsequent licensing arrangement to be negotiated, Beroni aims to bring the benefits from the Research to those*

affected by the targeted diseases.”

About Columbia University

Columbia University is one of the most prestigious institutions in the world. Its Medical Testing Center is a global leader in the fields of research, health and medical education, and patient care. Up to now, the Mailman School of Public Health has programs in more than 100 countries and is a leader in HIV/AIDS, public mental health, environmental health, global health, and urban health.

Professor Walter Ian Lipkin, MD, Professor of Epidemiology, Neurology and Pathology, Director of Center for Infection and Immunity, is internationally recognised as an authority on the use of molecular methods for pathogen discovery. He won the China International Science and Technology Cooperation Award in 2015, and he also was dubbed the “World’s Most Celebrated Virus Hunter”.

For further information please contact:

Mr Jacky Zhang
Executive Chairman
Tel: +86 1851 6931 911
E: 1710426553@qq.com

Mr Peter Wong
Non-Executive Director
Tel: +61 423 727 580
E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX:BTG) (FSE:6B9)

Beroni Group’s currently has four main products: NicoBloc, Fogibloc, Multi Vigorous tablets (Bei Jingli) and Multi lung cleaning tablets (Bei Feiqing). Beroni Group’s overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries. The Company is open to acquisition opportunities to expand the business and increase its market share.